OBJECTIVE: To assess whether there are evident adverse effects of 17 alpha-hydroxyprogesterone caproate after in utero exposure. METHODS: This study evaluated surviving children of mothers who participated in a multicenterplacebo-controlled trial of weekly intramuscular 17 alpha-hydroxyprogesterone caproate, with a 2:1 allocation to 17 alpha-hydroxyprogesterone caproate and placebo, respectively. The guardian was interviewed about the child's general health. Children underwent a physical examination and developmental screen with the Ages and Stages Questionnaire. Gender-specific roles were assessed with the Preschool Activities Inventory. RESULTS: Of 348 eligible surviving children, 278 (80%) were available for evaluation (194 in the 17 alpha-hydroxyprogesterone caproate group and 84 in the placebo group). The mean age at follow-up was 48 months. No significant differences were seen in health status or physical examination, including genital anomalies, between 17 alpha-hydroxyprogesterone caproate and placebo children. Scores for gender-specific roles (Preschool Activities Inventory) were within the normal range and similar between 17 alpha-hydroxyprogesterone caproate and placebo groups. CONCLUSION:17 alpha-hydroxyprogesterone caproate seems to be safe for the fetus when administered in the second and third trimesters.
RCT Entities:
OBJECTIVE: To assess whether there are evident adverse effects of 17 alpha-hydroxyprogesterone caproate after in utero exposure. METHODS: This study evaluated surviving children of mothers who participated in a multicenter placebo-controlled trial of weekly intramuscular 17 alpha-hydroxyprogesterone caproate, with a 2:1 allocation to 17 alpha-hydroxyprogesterone caproate and placebo, respectively. The guardian was interviewed about the child's general health. Children underwent a physical examination and developmental screen with the Ages and Stages Questionnaire. Gender-specific roles were assessed with the Preschool Activities Inventory. RESULTS: Of 348 eligible surviving children, 278 (80%) were available for evaluation (194 in the 17 alpha-hydroxyprogesterone caproate group and 84 in the placebo group). The mean age at follow-up was 48 months. No significant differences were seen in health status or physical examination, including genital anomalies, between 17 alpha-hydroxyprogesterone caproate and placebo children. Scores for gender-specific roles (Preschool Activities Inventory) were within the normal range and similar between 17 alpha-hydroxyprogesterone caproate and placebo groups. CONCLUSION:17 alpha-hydroxyprogesterone caproate seems to be safe for the fetus when administered in the second and third trimesters.
Authors: Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield Journal: Acta Obstet Gynecol Scand Date: 2011-06-27 Impact factor: 3.636
Authors: Richard S Legro; Michael P Diamond; Christos Coutifaris; William D Schlaff; Ruben Alvero; Peter Casson; Gregory M Christman; R Mitchell Rosen; Marcelle I Cedars; Karl R Hansen; Randal Robinson; Valerie Baker; Rebecca Usadi; William C Dodson; Stephanie J Estes; Allen Kunselman; Christina Stetter; Kurt T Barnhart; R Matthew Coward; J C Trussell; Stephen A Krawetz; Nanette Santoro; Hao Huang; Heping Zhang; Esther Eisenberg Journal: Fertil Steril Date: 2020-05 Impact factor: 7.329
Authors: Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Gary D Hankins; Menachem Miodovnik; Mary F Hebert; Jason G Umans; Thomas Benedetti; Donald Mattison; Anne Zajicek; Dawn Fischer; Aimee Jackson Journal: Am J Obstet Gynecol Date: 2012-08-16 Impact factor: 8.661